• MAY 16, 2000

Glenmark gains at Fulford’s cost

The dermatology segment (which deals with skin infections) of the pharmaceutical formulation industry has been witnessing a heavy dose of competition. While the overall formulation segment has grown at 9.8% for FY2000, this segment has grown at only 8.2%.

While the market leader Glaxo seems to have slightly increased its market share, a relatively smaller company, Glenmark Pharmaceuticals seems to be a major gainer at the cost of its bigger rivals Fulford and Ranbaxy. This seems to be primarily due to the marketing push the company has been given to its products particularly Candid, its dermatological brand which seems to be following in Glaxo’s footsteps.

As per the ORG data (see table) Glaxo remains the market leader by far, with a 16.9% market share in the dermatology segment. This is due to the fact that its Betnovate range of formulations have achieved near OTC status (Over the Counter) despite being prescription brands.

  Value (Rs m) Market Share Growth
Overall Value 7,549 100.0% 8.2%
Glaxo–Wellcome 1,278 16.9% 8.9%
Fulford 649 8.6% -7.3%
Ranbaxy–Croslands 471 6.2% 3.0%
Glenmark Pharma 434 5.8% 26.2%

Source ORG RSA Mar 2000

The surprise has however been an over 25% growth for Candid. Though one can argue that Glenmark’s growth has been from a much lower base (since Glaxo’s dermatological revenues almost equal the entire revenues of the Glenmark) this just shows the importance of brand building and establishing mind recall for pharma products and the benefits it yields during a slowdown in the industry.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407